Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program

Keyphrases

• 1-year Survival 20%
• Advanced Age 20%
• Adverse Events 20%
• Antitumor Activity 20%
• Best Supportive Care 20%
• Chemo-naive 100%
• Chemotherapy 60%
• Clinical Practice Guidelines 20%
• Comorbidity 20%
• Complete Response 20%
• Consecutive Patients 20%
• Diarrhea 20%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 20%
• Expanded Access 100%
• Gefitinib 100%
• Improved Survival 20%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Median Survival 20%
• Partial Response 20%
• Patient Refusal 20%
• Poor Performance Status 20%
• Pretreated Patients 20%
• Previous Chemotherapy 20%
• Rash 20%
• Response Rate 20%
• Retrospective Chart Review 20%
• Stable Disease 20%
• Subsequent Chemotherapy 20%
• Toxicity Profile 20%
• Treatment Failure 20%
• Treatment Toxicity 20%

Medicine and Dentistry

• Adverse Event 20%
• Antineoplastic Activity 20%
• Arm 20%
• Clinical Guideline 20%
• Comorbidity 20%
• Compassionate Use 100%
• Diarrhea 20%
• Diseases 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Exanthem 20%
• Gefitinib 100%
• Non Small Cell Lung Cancer 100%
• Patient History of Chemotherapy 20%
• Supportive Care 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Antitumor Activity 20%
• Chemotherapy 80%
• Comorbidity 20%
• Diarrhea 20%
• Diseases 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Gefitinib 100%
• Non Small Cell Lung Cancer 100%
• Patient History of Chemotherapy 20%
• Rash 20%